Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Andrew Blauvelt, Jonathan I. Silverberg, Charles W. Lynde, Thomas Bieber, Samantha Eisman, Jacek Zdybski, Walter Gubelin, Eric L. Simpson, Fernando Valenzuela, Paulo Ricardo Criado, Mark G. Lebwohl, Claire Feeney, Tahira Khan, Pinaki Biswas, Marco DiBonaventura, Hernan Valdez, Michael C. Cameron, Ricardo Rojo

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Fingerprint

Dive into the research topics of 'Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences